Catalyst Wire Dossier Catalyst Wire Dossier

Lumigan 0.01%

bimatoprost 0.01% · Allergan
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Lumigan 0.01%, covering 2024-07-18 to 2024-07-18. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients [Phase 3]

See pricing